Treatment of Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma: liver resection versus TACE and beyond.
作者信息
Huo Ya Ruth, Xiang Hao, Chan Michael Vinchill
机构信息
Department of Radiology, Concord Repatriation General Hospital, Concord, NSW, Australia.
Department of Interventional Radiology, Liverpool Hospital, Liverpool, NSW, Australia.
出版信息
Ann Transl Med. 2020 Oct;8(19):1209. doi: 10.21037/atm-20-4903.
Abstract
摘要
相似文献
1
Treatment of Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma: liver resection versus TACE and beyond.巴塞罗那临床肝癌C期肝细胞癌的治疗：肝切除术与经动脉化疗栓塞术及其他治疗方法的比较
Ann Transl Med. 2020 Oct;8(19):1209. doi: 10.21037/atm-20-4903.
2
Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.肝切除术与经肝动脉化疗栓塞术治疗巴塞罗那临床肝癌分期 B 期肝细胞癌的比较。
Hepatol Int. 2018 Sep;12(5):417-428. doi: 10.1007/s12072-018-9888-4. Epub 2018 Aug 2.
3
Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.经导管动脉化疗栓塞联合或不联合射频消融治疗巴塞罗那临床肝癌分期 B 期肝细胞癌的疗效比较。
AJR Am J Roentgenol. 2018 Apr;210(4):891-898. doi: 10.2214/AJR.17.18177. Epub 2018 Feb 7.
4
Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients.巴塞罗那临床肝癌指南内外肝癌切除术后治愈机会的定义：1010 例多机构分析。
Surgery. 2019 Dec;166(6):967-974. doi: 10.1016/j.surg.2019.08.010. Epub 2019 Oct 9.
5
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.经动脉化疗栓塞术在肝细胞癌治疗中的应用：巴塞罗那临床肝癌分期系统
World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327.
6
Liver resection is associated with good outcomes for hepatocellular carcinoma patients beyond the Barcelona Clinic Liver Cancer criteria: A multicenter study with the Hiroshima Surgical study group of Clinical Oncology.对于超出巴塞罗那临床肝癌标准的肝细胞癌患者，肝切除与良好预后相关：一项与广岛临床肿瘤外科学术研究组合作的多中心研究。
Surgery. 2022 May;171(5):1303-1310. doi: 10.1016/j.surg.2021.09.009. Epub 2021 Oct 30.
7
[Comparison liver resection with transarterial chemoembolization for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma patients on long-term survival after SPSS propensity score matching].[巴塞罗那临床肝癌分期B期肝细胞癌患者经SPSS倾向评分匹配后肝切除与经动脉化疗栓塞术对长期生存的比较]
Zhonghua Yi Xue Za Zhi. 2014 Mar 18;94(10):747-50.
8
Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.对比中期肝细胞癌手术切除与肝动脉化疗栓塞联合或不联合射频消融的总生存率：倾向评分匹配分析。
BMC Gastroenterol. 2020 Apr 10;20(1):99. doi: 10.1186/s12876-020-01235-w.
9
Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.经动脉化疗栓塞联合微波消融及阿帕替尼治疗巴塞罗那临床肝癌分期C期肝细胞癌患者：一项倾向评分匹配分析
J Cancer Res Ther. 2020;16(2):250-257. doi: 10.4103/jcrt.JCRT_345_19.
10
Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?巴塞罗那临床肝癌分期B期肝细胞癌：经动脉化疗栓塞术还是肝切除术？
Medicine (Baltimore). 2014 Nov;93(26):e180. doi: 10.1097/MD.0000000000000180.
本文引用的文献
1
Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma.确定不可切除肝细胞癌患者中肝切除或经动脉化疗栓塞的最佳候选者。
Ann Transl Med. 2020 May;8(9):586. doi: 10.21037/atm.2020.02.83.
2
Future liver remnant function as a predictor of postoperative morbidity following liver resection for hepatocellular carcinoma - A risk factor analysis.未来肝脏残存量作为肝癌肝切除术后术后发病率的预测指标 - 风险因素分析。
Surg Oncol. 2020 Jun;33:257-265. doi: 10.1016/j.suronc.2020.02.004. Epub 2020 Feb 8.
3
Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus.经动脉消融性放射栓塞术可改善伴门静脉癌栓 HCC 患者的生存。
Cardiovasc Intervent Radiol. 2020 Mar;43(3):411-422. doi: 10.1007/s00270-019-02404-5. Epub 2020 Jan 6.
4
Resection Plus Post-operative Adjuvant Transcatheter Arterial Chemoembolization (TACE) Compared with Resection Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.切除术联合术后经导管动脉化疗栓塞术（TACE）与单纯切除术治疗肝细胞癌的比较：系统评价和荟萃分析。
Cardiovasc Intervent Radiol. 2020 Apr;43(4):572-586. doi: 10.1007/s00270-019-02392-6. Epub 2020 Jan 2.
5
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.REFLECT 研究：比较仑伐替尼与索拉非尼治疗不可切除肝细胞癌的疗效和安全性的 3 期临床试验：日本亚组分析。
J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12.
6
Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma.放射段切除术：早期肝细胞癌的潜在治愈性治疗方法。
Radiology. 2018 Jun;287(3):1050-1058. doi: 10.1148/radiol.2018171768. Epub 2018 Apr 24.
7
Integration of Child-Pugh score with future liver remnant yields improved prediction of liver dysfunction risk for HBV-related hepatocellular carcinoma following hepatic resection.将Child-Pugh评分与未来肝剩余体积相结合，可改善对乙型肝炎病毒相关肝细胞癌肝切除术后肝功能障碍风险的预测。
Oncol Lett. 2017 May;13(5):3631-3637. doi: 10.3892/ol.2017.5919. Epub 2017 Mar 27.
8
Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.经动脉化疗栓塞术（TACE）与索拉非尼联合应用可改善巴塞罗那临床肝癌（BCLC）分期B/C期肝细胞癌患者的预后：单中心经验
Ann Hepatol. 2017 March-April;16(2):247-254. doi: 10.5604/16652681.1231583.
9
Reducing inflow occlusion, occlusion duration and blood loss during hepatic resections.减少肝切除术中的入肝血流阻断、阻断持续时间和失血量。
ANZ J Surg. 2018 Jan;88(1-2):E25-E29. doi: 10.1111/ans.13711. Epub 2016 Oct 27.
10
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.切除术后使用索拉非尼可改善BCLC C期肝细胞癌的预后。
World J Gastroenterol. 2016 Apr 21;22(15):4034-40. doi: 10.3748/wjg.v22.i15.4034.
Zotero 插件